Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia

Journal of the American College of Cardiology

Volumn 51, Issue 16, 2008, Pages 1564-1572

  Guyton, John R ^a   Brown, B Greg ^b   Fazio, Sergio ^c   Polis, Adam ^d   Tomassini, Joanne E ^d   Tershakovec, Andrew M ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GALLBLADDER DISEASE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; NIACIN; SIMVASTATIN;

EID: 41949131921     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.003     Document Type: Article

References (38)

1. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
2. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 47 (2006) 2130-2139
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106 (2002) 3143-3421
4. Sanyal S., Karas R.H., and Kuvin J.T. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert Opin Pharmacother 11 (2001) 1711-1717
5. Brown B.G., Zhao X.Q., and Cheung M.C. Should both HDL-C and LDL-C be targets for lipid therapy?. A review of current evidence. J Clin Lipidol 1 (2007) 88-94
6. Guyton J.R. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18 (2007) 415-420
7. Niaspan [product insert]. N. Chicago, IL: Abbott Laboratories, 2007.
8. Goldberg A., Alagona Jr. P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
9. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 (1998) 1097-1104
10. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
11. Duvall W.L., Blazing M.A., Saxena S., and Guyton J.R. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. J Cardiovasc Risk 9 (2002) 339-347
12. Bays H.E., Dujovne C.A., McGovern M.E., et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (The ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91 (2003) 667-672
13. Capuzzi D.M., Morgan J.M., Carey C.M., et al. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol 7 (2004) 176-181
14. Kashyap M.L., McGovern M.E., Berra K., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89 (2002) 672-678
15. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
16. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
17. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2-a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
18. Kane J.P., Malloy M.J., Ports T.A., et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 (1990) 3007-3012
19. Carlson L., and Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
20. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
21. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1974) 360-381
22. Ballantyne C.M., Abate N., Yuan Z., King T.R., and Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 149 (2005) 464-473
23. Bays H.E., Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
24. Catapano A.L., Davidson M.H., Ballantyne C.M., et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 22 (2006) 2041-2053
25. Vytorin. [product insert] (2003), Merck/Schering-Plough Pharmaceuticals, North Wales, PA
26. Guyton J.R., and Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 99 (2007) 22C-31C
27. American Diabetes Association. Standards of Medical Care. Diabetes Care 30 Suppl (2007) S4-S41
28. O'Riordan M. Trial testing benefits of raising HDL cholesterol to be launched by Oxford researchers. www.theheart.org Accessed May 31, 2006.
29. Cefali E.A., Simmons P.D., Stanek E.J., and Shamp T.R. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharm Ther 44 (2006) 633-640
30. Merck/Schering Plough Pharmaceutical analysis of data from IMS Health. Whitehouse Station, NJ: NPA Monthly, 2007.
31. Zhao X.Q., Morse J.S., Dowdy A.A., et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93 (2004) 307-312
32. Guyton J.R., Goldberg A.C., Kreisberg R.A., et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82 (1998) 737-743
33. Zhao X.Q., Phan B.A., Chu B., et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J 154 (2007) 239-246
34. Niacin Plus Statin to Prevent Vascular Events. http://www.clinicaltrials.gov/ct2/show/NCT00120289?term=NCT00120289& rank=1 Accessed March 20, 2008.
35. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. http://www.clinicaltrials.gov/ct2/show/NCT00461630 Accessed March 20, 2008.
36. Rossebø A., Pedersen T., Allen C., et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol 99 (2007) 970-973
37. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 63 (2003) S207-S210
38. Cannon C.P., Guigliano R.P., Blazing M.A., et al. Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am Heart J (2008) In press.